Opinion
Video
A panel of experts on colorectal cancer have a comprehensive discussion on adverse events associated with TAS-102 plus bevacizumab and strategies to mitigate them.
NGC-Cap Demonstrates Preliminary Efficacy in Stage III/IV GI Cancer
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Amphiphile Lymph Node–Targeted Vaccine Is Safe and Bolsters T-Cell Responses in MRD+ PDAC and CRC
D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor
Olverembatinib Demonstrates Early Activity, Tolerability in SDH-deficient GIST
Bevacizumab Biosimilar Avzivi Receives Positive CHMP Opinion
Dr Bertossi on the Prognostic Role of TP53 Mutations in CLL
Dr Grunwald on the Rates of Disease Progression in Low-Risk Myelofibrosis
Zanubrutinib Plus Obinutuzumab/Venetoclax Is Safe, Elicits Responses in Older Patients With Untreated MCL
Earlier Use of Acalabrutinib Associated With Improved Survival in CLL